



**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:


1. (currently amended) A compound of the Formula IA, IB, IIA, IIB, IIIA or IIIB:




IA




IB




IIA



IIB



IIIA



IIIB

wherein:

$R^1$  is selected from the group consisting of  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl and benzyl, each of which is optionally substituted with 1 to 3 substituents independently selected at each occurrence from  $C_1$ - $C_3$  alkyl, halogen, -CN, -OR<sup>8</sup> and -NR<sup>8</sup>R<sup>9</sup>;

$R^2$  is selected from the group consisting of H,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl and  $C_1$ - $C_6$  haloalkyl;

$R^3$  is selected from the group consisting of H, halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl and  $C_3$ - $C_6$  cycloalkyl, wherein  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  haloalkyl and  $C_3$ - $C_6$  cycloalkyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from OR<sup>8</sup> and NR<sup>8</sup>R<sup>9</sup>;

$R^4$ ,  $R^5$  and  $R^6$  are each independently selected at each occurrence thereof from the group consisting of H, halogen, -OR<sup>10</sup>, -NO<sub>2</sub>, NR<sup>10</sup>R<sup>11</sup>, -NR<sup>10</sup>C(O)R<sup>11</sup>, -NR<sup>10</sup>C(O)NR<sup>11</sup>R<sup>12</sup>, -S(O)<sub>n</sub>R<sup>11</sup>, -CN, -C(O)R<sup>11</sup>, -C(O)<sub>2</sub>R<sup>11</sup>, -C(O)NR<sup>11</sup>R<sup>12</sup>,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl and  $C_4$ - $C_7$  cycloalkylalkyl, wherein each of  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_6$  cycloalkyl and  $C_4$ - $C_7$  cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from  $C_1$ - $C_3$  alkyl, halogen, =O, -CN, -OR<sup>8</sup>, -NR<sup>8</sup>R<sup>9</sup> and phenyl, and wherein phenyl is optionally substituted with 1-3 substituents selected independently at each occurrence from halogen, -CN,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, -OR<sup>8</sup> and -NR<sup>8</sup>R<sup>9</sup>; alternatively  $R^5$  and  $R^6$  are -O-C(R<sup>11</sup>)<sub>2</sub>-O-;

$R^7$  is selected from the group consisting of H, halogen and OR<sup>10</sup>;

$R^8$  and  $R^9$  are each independently selected from the group consisting of H,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxyalkyl,  $C_1$ - $C_4$  alkoxyalkylalkyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl, -C(O)R<sup>12</sup>, phenyl and benzyl, wherein phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxy and  $C_1$ - $C_4$  haloalkoxy;

$R^{10}$  is selected from the group consisting of H,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxyalkyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl, -C(O)R<sup>12</sup>, phenyl and benzyl, wherein phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen, -NH<sub>2</sub>, -OH, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxy and  $C_1$ - $C_4$  haloalkoxy;

$R^{11}$  is selected from the group consisting of H,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  alkoxyalkyl,  $C_3$ - $C_6$  cycloalkyl,  $C_4$ - $C_7$  cycloalkylalkyl, phenyl and benzyl, where phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each

occurrence from halogen, -NH<sub>2</sub>, -OH, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy;

R<sup>12</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl and phenyl;


X is selected from the group consisting of O, NR<sup>13</sup> and S, with the proviso that X is not NR<sup>13</sup> when a compound is of Formula (IA);

n is 0, 1, or 2; and,

R<sup>13</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl and phenyl, wherein C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl and phenyl are optionally substituted with 1-3 substituents selected independently at each occurrence from halogen, -NH<sub>2</sub>, -OH, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy.

2. (original) The compound of claim 1, wherein R<sup>1</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl.
3. (original) The compound of claim 2, wherein R<sup>1</sup> is CH<sub>3</sub>.
4. (original) The compound of claim 1, wherein R<sup>2</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, or C<sub>1</sub>-C<sub>6</sub> haloalkyl.
5. (original) The compound of claim 4, wherein R<sup>2</sup> is H or C<sub>1</sub>-C<sub>6</sub> alkyl.
6. (original) The compound of claim 5, wherein R<sup>2</sup> is H.
7. (original) The compound of claim 1, wherein R<sup>3</sup> is at each occurrence thereof independently H, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, or C<sub>1</sub>-C<sub>6</sub> alkyl substituted with from 1 to 3 of OR<sup>8</sup> or NR<sup>8</sup>R<sup>9</sup>.
8. (original) The compound of claim 7, wherein R<sup>3</sup> is H or C<sub>1</sub>-C<sub>6</sub> alkyl.
9. (original) The compound of claim 8, wherein R<sup>3</sup> is H.
10. (original) The compound of claim 1, wherein R<sup>1</sup> is CH<sub>3</sub>, R<sup>2</sup> is H and R<sup>3</sup> is H.


11. (original) The compound of claim 1, wherein  $R^4$ ,  $R^5$  and  $R^6$  are each independently H, halogen,  $C_1$ - $C_6$  alkyl or  $-OR^{10}$ .
12. (original) The compound of claim 11, wherein at least one of  $R^4$ ,  $R^5$  and  $R^6$  is H.
13. (original) The compound of claim 12, wherein each of  $R^4$ ,  $R^5$  and  $R^6$  are H.
14. (original) The compound of claim 12, wherein one of  $R^4$ ,  $R^5$  and  $R^6$  is halogen.
15. (original) The compound of claim 1, wherein  $R^1$  is  $CH_3$ ,  $R^2$  and  $R^3$  are each H, and at least one of  $R^4$ ,  $R^5$  and  $R^6$  is H.
16. (currently amended) A The compound of Formula (10) of claim 1, wherein the compound has a structure of Formula (10):



or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

- a compound of Formula (10) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (10) wherein  $R^4$  is H,  $R^5$  is Me and  $R^6$  is H;
- a compound of Formula (10) wherein  $R^4$  is Cl,  $R^5$  is H and  $R^6$  is H; and
- a compound of Formula (10) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H.


17. (currently amended) ~~A~~ The compound of Formula (20) of claim 1,  
wherein the compound has a structure of Formula (20):



or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

- a compound of Formula (20) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (20) wherein  $R^4$  is H,  $R^5$  is Me and  $R^6$  is H;
- a compound of Formula (20) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is H;
- a compound of Formula (20) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H; and
- a compound of Formula (20) wherein  $R^4$  is F,  $R^5$  is H and  $R^6$  is F.

18. (currently amended) ~~A~~ The compound of Formula (30) of claim 1,  
wherein the compound has a structure of Formula (30):



or a pharmaceutically acceptable salt form thereof selected from the group consisting of:


- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is F and  $R^6$  is H;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is F;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is H;

a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;  
 a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl;  
 a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is Cl;  
 a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H;

and

a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is H.

19. (currently amended) A The compound of Formula (40) of claim 1,  
wherein the compound has a structure of Formula (40):



or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;  
 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is F and  $R^6$  is H;  
 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is F;  
 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is H;  
 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;  
 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is H and  $R^6$  is H;  
 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is H;  
 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;  
 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl;  
 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is Cl;  
 a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H;  
 a compound of Formula (40) wherein  $R^3$  is Me,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;  
 a compound of Formula (40) wherein  $R^3$  is Et,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;


and

a compound of Formula (40) wherein  $R^3$  is  $\text{CH}_2\text{OH}$ ,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H.

Claims 20-22 (canceled)

23. (currently amended) ~~A~~ The compound of Formula (80) of claim 1,  
wherein the compound has a structure of Formula (80):

(80)




or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

- a compound of Formula (80) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (80) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H; and
- a compound of Formula (80) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.

24. (currently amended) ~~A~~ The compound of Formula (90) of claim 1,  
wherein the compound has a structure of Formula (90):

(90)




or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

- a compound of Formula (90) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H.
- a compound of Formula (90) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F; and
- a compound of Formula (90) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H.

Claim 25 (canceled)


26. (currently amended) A The compound of Formula (110) of claim 1,  
wherein the compound has a structure of Formula (110):



or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

- a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F;
- a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;
- a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is Cl;
- a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;
- a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl; and
- a compound of Formula (110) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H.

27. (currently amended) A The compound of Formula (120) of claim 1,  
wherein the compound has a structure of Formula (120):



or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

- a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F;
- a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;




- a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is Cl;
- a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;
- a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H; and
- a compound of Formula (120) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl.

Claim 28 (canceled)

29. (currently amended) ~~A~~ The compound of Formula (140) of claim 1,  
wherein the compound has a structure of Formula (140):

(140)




or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

- a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;
- a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl;
- a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;
- a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is Cl;
- a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H; and
- a compound of Formula (140) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.

30. (currently amended) ~~A~~ The compound of Formula (150) of claim 1,  
wherein the compound has a structure of Formula (150):

(150)




or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

- a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;
- a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl;
- a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;
- a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is Cl;
- a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H; and
- a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.

Claim 31 (canceled)

32. (currently amended) A The compound of ~~Formula (170)~~ of claim 1, wherein the compound has a structure of Formula (170):


(170)



or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

- a compound of Formula (170) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (170) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H; and
- a compound of Formula (170) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.

33. (currently amended) A The compound of Formula (180) of claim 1,  
wherein the compound has a structure of Formula (180):



or a pharmaceutically acceptable salt form thereof selected from the group consisting of:

- a compound of Formula (180) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
- a compound of Formula (180) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is H; and
- a compound of Formula (180) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is F.

Claims 34-35 (canceled)

36. (original) A compound of claim 1 selected from the group consisting of:

- (R)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-*h*]isoquinoline;
- (S)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-*h*]isoquinoline;
- (R)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-*g*]isoquinoline;
- (S)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-*g*]isoquinoline;
- (R)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;
- (S)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;
- (R)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;
- (S)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo [2,3-*h*]isoquinoline;
- (R)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;
- (S)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;
- (R)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;
- (S)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;
- (R)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-*h*]isoquinoline;

(S)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-*h*]isoquinoline;  
 (R)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (S)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (R)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (S)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (R)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1*H*-pyrrolo[2,3-*h*]isoquinoline; and  
 (S)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1*H*-pyrrolo[2,3-*h*]isoquinoline.

37. (original) A compound of claim 1 selected from the group consisting of:

(+)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-*h*]isoquinoline;  
 (-)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-*h*]isoquinoline;  
 (+)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-*g*]isoquinoline;  
 (-)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-*g*]isoquinoline;  
 (+)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (-)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (+)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (-)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (+)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (-)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (+)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (-)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (+)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-*h*]isoquinoline;  
 (-)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-*h*]isoquinoline;  
 (+)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (-)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (+)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (-)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-*h*]isoquinoline;  
 (+)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1*H*-pyrrolo[2,3-*h*]isoquinoline; and

(-)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1*H*-pyrrolo[2,3-*h*]isoquinoline.

38. (original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.

39. (original) A method of treating an animal afflicted with a neurological or psychological disorder selected from the group consisting of attention deficit-hyperactivity disorder, anxiety, depression, post-traumatic stress disorder, supranuclear palsy, feeding disorders, obsessive compulsive disorder, analgesia, smoking cessation, panic attacks, Parkinson's and phobia, said method comprising administering to the animal the pharmaceutical composition of claim 38.

40. (original) The method of claim 39 for treating attention deficit-hyperactivity disorder.